March 26th 2025
Kansas now has an outbreak with at least 10 confirmed cases with an expectation from the state's health officials that there will be more.
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
Charting the Path to Precision Diagnosis: Detection and Treatment Approaches for Oncogenic Mutations in NSCLC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Burst CME™: Stepping Up Care for Patients With PAH
View More
Did Full FDA Approval of the Pfizer-BioNTech Vaccine Increase COVID-19 Vaccinations?
April 6th 2022After the US Food and Drug Administration (FDA) fully authorized the Pfizer-BioNTech mRNA vaccine, series-completing second doses increased substantially. However, first vaccine doses were actually administered at lower rates after the approval.
Read More
In Children Under 5, Omicron COVID-19 Infection Was More Likely, But Delta Was More Severe
April 2nd 2022Children under 5 became infected with the Omicron variant 6-8 times more frequently than young children who contracted Delta. However, Delta COVID-19 infections were more severe than Omicron.
Read More
NIH Launches Trial Evaluating Second COVID-19 Booster Shots
March 31st 2022One day after the FDA approved second booster shots for certain vulnerable populations, the National Institute of Health (NIH) announced they have begun enrolling adult US participants in a phase 2 clinical trial to evaluate a second COVID-19 booster dose.
Read More
Sotrovimab Distribution Paused in Areas Where BA.2 Is Dominant COVID-19 Variant
March 28th 2022The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.
Read More
Type 2 Diabetes Diagnosis More Likely After COVID-19 Infection
March 21st 2022A matched cohort study found COVID-19 infection increased the risk of new type 2 diabetes diagnosis. Compared to patients with acute upper respiratory tract infections, COVID-19 patients were 28% more likely to develop diabetes.
Read More
“Most Transmissible Variant” BA.2 Expected to Overtake Original Omicron Strain
March 21st 2022There are many unknowns about the BA.2 COVID-19 variant. It appears 50-60% more transmissible than the original Omicron variant, but health experts are mixed on whether cases will spike dramatically.
Read More
Children’s Duration of COVID-19 Immunity from Natural Infection
March 19th 2022A Texas study found children and adolescents who previously contracted COVID-19 retained protective antibodies for 6 or more months after infection. However, natural infection plus vaccination remains the best defense against COVID-19.
Read More
With New Variants, COVID-19 Vaccination Mildly Effective in Children
March 15th 2022In children and adolescents, the Pfizer-BioNTech vaccine was only mildly effective against symptomatic and asymptomatic COVID-19 infections. Broken down by variant, Omicron infections were more likely to occur and more likely to be asymptomatic.
Read More